Research suggests that the structure of a specific molecule, the branched N-glycan of PD-L1, may be linked to how well patients with a certain type of cancer respond to immunotherapy. The relationship between glycosylation, or the addition of sugar molecules to proteins, and cancer is being explored in various studies. The role of glycosylation in cancer progression and immunotherapy response is a topic of ongoing research, with potential implications for understanding and treating different types of cancer.